Takeda posts Phase 2 TAK-101 celiac results; registers two observational studies

Takeda had three program updates during the week, led by results from a completed Phase 2 celiac disease trial.

• TAK-101 is a Phase 2 drug being tested for treating people who have celiac disease.¹ The study aims to assess whether TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease on a gluten-free diet.¹ The trial reached a completed status with enrollment of 102 participants (actual)¹, and results were first posted on 2026-10-06.
• "KAPTURE-PV" is a new non-interventional observational study examining how physicians diagnose and treat polycythemia vera. The study is focused on PV, a rare, long-term blood cancer that causes the body to make too many blood cells, which can make the blood thicker than normal and raise the risk of blood clots.² It is estimated to enroll 90 participants² and has a status of not yet recruiting, with an estimated start of 2026-12-01.²
• The K-SIDE Study is a new retrospective observational study on secondary immunodeficiencies in adults with blood cancers in Kazakhstan. The study will use existing health records and data from Kazakhstan's national oncology registry rather than collecting new data.³ It is estimated to enroll 200 participants³ and is listed as not yet recruiting, with an estimated start of 2027-04-01.³